One item I overlooked was working capital $1.675M, as like most others CET funding was the prime focus.
So has funding in DX arena been shuftied into this bucket?
Anyway if would be good to hear if Anteotech NXT has been picked up in the Immunothearpy CAR T field of studies. I believe that Binder application is a pivotal part in CAR T thearpy outcomes.
Ann: Prospectus - Share Purchase Plan Offer and Options Offer, page-5
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
